BioSpace News Archive

Business

Widespread Distribution of a COVID-19 Vaccine Could Take As Long as 2024

Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.

September 15, 2020
·
3 min read
·
Mark Terry
Drug Development

Marinus’ Ganaxolone Hits the Mark in Phase III Genetic Epilepsy Study

Shares of Marinus Pharmaceuticals soared more than 60% in after-hours trading Monday following the company’s announcement that its experimental epilepsy treatment ganaxolone hit the mark in a Phase III study.

September 15, 2020
·
2 min read
·
Alex Keown
Business

New Artificial Pancreas Offers Hope for Children with Poorly Controlled Type 1 Diabetes

The study, led by U.S. researchers, showed that the novel system was safe and effective for managing blood glucose in children as young as 6 years old.

September 15, 2020
·
4 min read
·
Brandon May
Policy

BioNTech Receives €375 Million German Grant to Help Fund COVID-19 Vaccine Effort

Only days after saying it expects to have key data from its Phase III clinical trial of its COVID-19 vaccine in October, Germany’s BioNTech received a grant of up to €375 million from the German Federal Ministry of Education and Research.

September 15, 2020
·
3 min read
·
Mark Terry
Business

Takeda Expands Cell Therapy Efforts with New R&D Manufacturing Plant in Boston

Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston, Massachusetts. It is at the site of the company’s R&D headquarters.

September 15, 2020
·
3 min read
·
Mark Terry
Business

Stem Cells May Help COVID-19 and ARDS Patients Breathe Easier

One company working towards an ARDS treatment is Athersys, a biotech company focusing on regenerative medicine therapies for diseases with significant unmet need.

September 15, 2020
·
11 min read
·
Chelsea Weidman Burke
Biotech Bay

ESCAPE Bio Snags $73 Million to Advance Neurodegenerative Clinical Development Programs

Clinical-stage biopharmaceutical firm ESCAPE Bio has snagged a $73 million crossover financing deal, led by Wellington Management Company, which will help advance the company’s two clinical development programs of precision neurology medicines for patients with genetic neurodegeneration.

September 15, 2020
·
2 min read
·
Brandon May
Pharm Country

iBio’s FastPharming® Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2

Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment.

September 15, 2020
·
4 min read
·
Gail Dutton
Career Advice

Why and How to Avoid Becoming a Workaholic

The life science industry produces a complex, high-stress and intricate work environment, so it’s no surprise that workaholics pop up in this industry all the time.

September 15, 2020
·
3 min read
·
Kymberlie Krieger
Policy

UAE Grants Emergency Use for COVID-19 Vaccine for Healthcare Workers

The United Arab Emirates has granted Emergency Use Authorization to an investigational vaccine for the novel coronavirus six weeks after late-stage studies began.

September 15, 2020
·
2 min read
·
Alex Keown